Exchange: OTC·Updated 12:12 PM EST

RVVTF Revive Therapeutics Ltd

$0.0096
$0.0009
(8.57%)
Today
Mkt Cap$4.66M
Vol177,851.00

About RVVTF

Revive Therapeutics Ltd. engages in the research, development, and commercialization of drugs for disorders and infectious diseases. The company was founded by Fabio Chianelli on March 27, 2012 and is headquartered in Toronto, Canada.
36

Bearish Sentiment

How do you feel about RVVTF?

Canadianbull1324
$RVVTF Topics directly related to nerve agent exposure and defence research were core focal points of the recent Defence Growth Forum, which took place on October 28–29, 2026, in Medicine Hat, Alberta. While specific commercial entity names like Revive Therapeutics (CSE: RVV) or their specific drug candidate bucillamine were not explicitly broadcasted as standalone session titles, their exact research context took center stage during the forum's most prominent technical briefings.
8
Canadianbull1324
$RVVTF My mistake....Following the positive data released in August 2026, Revive and the DRDC officially firmed up their next steps. Instead of jumping to human testing, they explicitly scheduled preclinical confirmatory studies to begin in Q4 2026 to look closer at specific markers like brain injury, oxidative stress, and respiratory function.
7
Barron401k
$RVVTF Volume went quiet 10-16. Today is day 25. In trading days, that's Day 17 of 30. Day 30 is around Friday the 27th. I think my volume drop thesis is viable. Also of note - Nov 16 - 7.7 million shares from the private placement come off their 4 month lock. So...
1
3
Canadianbull1324
$RVVTF this news is good, slower cash burn rate. Based on the clinical trial phase and historical timelines we could be looking at a major catalyst late 2027 to mid 2028. They will launch the next phase before the end of this year. Let's goooooo 🥳
6
LifesGood
$RVVTF Aside from the formal December 9th milestone [cite: 25], any sudden momentum for $RVVTF usually hinges on a few specific operational catalysts dropping out of the blue: Official DRDC Study Results: Formal updates or final data releases regarding the Defence R&D Canada bucillamine nerve-agent countermeasure evaluations [cite: 1.1.2]—especially anything expanding on safety or CNS/GABA protection advantages over standard oximes. Partnership or Grant Announcements: Given the wider push for government defense contracts in this space (similar to recent sector deals like Kindeva's $226M autoinjector contract [cite: 20]), any non-dilutive funding, government partnership, or licensing agreement update would act as an immediate catalyst. Filing Drops / Share Structure Clarity: Updates on the private placement tranches [cite: 1.1.1] or official notices ahead of the shareholder meeting regarding call-in details [cite: 25].
6
LifesGood
$RVVTF DRDC Study Updates: Final authorizations and deeper findings regarding the Defence R&D Canada (DRDC) bucillamine nerve-agent countermeasures study remain on the radar, especially following earlier preclinical safety data comparing it to NAC [cite: 38]. December 9th Shareholder Meeting: Discussions center around whether management will open the meeting for live shareholder call-ins and whether any strategic updates or partnership developments will be unveiled [cite: 25]
4
BobWarner99
$RVVTF How long can RVVTF keep the Otcmarkets Pink Limited tag before another tag is applied?
3
Dirtymartini66
$RVVTF Bottom Line from the Ai Analysis (page 3 of my post) - pretty darn bullish if you ask me - so far so good with DRDC studies! The Practical Outlook If Bucillamine completes successful clinical trials for biodefense, it will likely be incorporated into the standard Chemical, Biological, Radiological, and Nuclear (CBRN) protocol alongside standard countermeasures. In this framework, a soldier or patient would receive an immediate ATNAA administration to survive the initial exposure, followed by Bucillamine to preserve brain and lung functionality against the long-term cellular trauma and inflammation that nerve agents leave behind.
3
BobWarner99
$RVVTF If the day ever comes where this hits .077+ cents. I will most definitely may need to partake in a beverage with a little kick to it. If this ever decides to run hard could it be one of those Pennies people end up talking about for yearss? We'll see. Either way I'm so very much interested in how the RVVTF story unfolds.....
2
Barron401k
$RVVTF If volume picks up between now and Thanksgiving - we might see fireworks right after
2
Dirtymartini66
$RVVTF today being a crummy day in the market isn't helping - $GOOG slaughter pretty much killing markets - everyone knows - GOOG is the better buy here - especially since RVV is dead money for another year or so.
2
Barron401k
$RVVTF anyone watching volume charts? I'm being you can set a clock to the 30 day insider trading window by the volume completely drying up! Who's got it?
2
Dirtymartini66
$RVVTF I saw the Kendeva Post about the $266 Million contract and had to look into what they had vs Buci - I put it through Google Ai - and shared the answer. I like that Buci - even though not a replacement is being looked at as an add on to ATNAA - gold standard - to help protect against down stream effects - different biological pathways - so not a competitive product - but rather a complimentary product - breathed a sigh of relief - because that's a much tougher mountain to scale if Buci were going head to head with the gold standard
2
BobWarner99
$RVVTF No News until December 2026....maybe?? Might we get an update on the confirmation studies before year's end? The 4th quarter of 2026?? 🤔
1
robma
$RVVTF any chance this turd goes back under a penny? Hasn't been good the past few weeks.

Advertisement|Remove ads.